Cargando…
Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials
BACKGROUND: The efficacy and safety of gefapixant in adults with chronic cough remain unclear. Our objective was to assess the efficacy and safety of gefapixant using updated evidence. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase databases were searched from...
Autores principales: | Chuang, Min-Hsiang, Chen, I-Wen, Chen, Jen-Yin, Kang, Fu-Chi, Ho, Chun-Ning, Wu, Shao-Chun, Yew, Ming, Lan, Kuo-Mao, Hung, Kuo-Chuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189640/ https://www.ncbi.nlm.nih.gov/pubmed/37197770 http://dx.doi.org/10.1183/16000617.0219-2022 |
Ejemplares similares
-
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
por: Birring, Surinder S., et al.
Publicado: (2023) -
The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough
por: McGarvey, Lorcan, et al.
Publicado: (2023) -
Efficacy of Gefapixant, a P2X(3) Antagonist, for Refractory Atopic Cough
por: Ishiura, Yoshihisa, et al.
Publicado: (2023) -
Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials
por: Abu-Zaid, Ahmed, et al.
Publicado: (2021) -
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020)